Navigation Links
Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop
Date:10/1/2009

The Drug Information Association (DIA) and the US Food and Drug Administration (USFDA) will host Assessing Benefits and Risks of Medicinal Products in Regulatory Decisions from November 3- 5, 2009 in Bethesda, MD.

Horsham, PA (Vocus) September 30, 2009 -- The Drug Information Association (DIA) and the US Food and Drug Administration (USFDA) will host Assessing Benefits and Risks of Medicinal Products in Regulatory Decisions from November 3- 5, 2009 in Bethesda, MD

High-level representatives from FDA, EMEA and Health Canada, along with patient advocates, industry professionals, and academics will explore the evolving world of benefit-risk assessment. Featured regulatory participation will include:

 
  • Eric Abadie, MD, European Medicines Agency (EMEA)
  • Janet Woodcock, MD, CDER, FDA
  • Kaoru Misawa, Pharmaceuticals and Medical Devices Agency (PMDA)
  • Robyn Lim, Health Canada

Participants will learn how scientific approaches applied in other fields can aid in decision analysis, approaches and methods to enhance transparency and communication of benefit-risk decisions, ways to overcome the challenges of implementing exploratory approaches to benefit-risk assessment in a regulatory framework, and processes and methods that may enhance regulatory decision making. Session topics will include:
 
  • Ongoing Initiatives to Test Structured Benefit-Risk Assessments
  • Methods for Valuing Risks and Benefits
  • Case Studies of Benefit-Risk Assessment
  • The Place of Models for Benefit-Risk Assessment
  • Processes for Reaching Group Decisions on Benefit-Risk Assessments
  • Characterizing Uncertainty: Grappling with the Unknown
  • Interfacing Benefit-Risk Assessment with Health Technology Assessment and Comparative Effectiveness for the Payor’s Perspective
  • Integrating Benefit-Risk into Early Development of New Products
  • Communicating Benefit-Risk to the End User—Patients
  • Panel Session with representatives from FDA, EMEA, PMDA, Health Canada, academia and patient advocacy groups
Baruch Fischhoff, PhD, Howard Heinz University Professor, Department of Social and Decision Sciences
Carnegie Mellon University; Chair, FDA Risk Communication Advisory Committee, will deliver the keynote address.

Click here to register.

About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.

###

Read the full story at http://www.prweb.com/releases/Drug_Information_FDA/Medicinal_Products/prweb2971364.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Global Biofuels Growth to Double by 2015
2. DIA Conference to Provide FDA, EMEA, Health Canada, Emerging Regions, NGO, and Industry Perspectives on Global Vaccine Development
3. Global Public Health the Focus of Scientific Conference
4. Global Med Technologies(R) Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product
5. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
6. Fortebio, Inc. to Present at UBS Global Life Sciences Conference
7. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
8. Covance to Present at UBS Global Life Sciences Conference
9. NeurogesX to Present at UBS Global Life Sciences Conference
10. Clinical Trials Move to Emerging Regions, Heighten Need for Local Risk Consulting: Aon Global Risk Map
11. Kensey Nash to Present at the 2009 UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop
(Date:5/3/2016)... , May 3, 2016 ... Assessing Developers and Producers of Those Competitor Biologics  ... to Companies, Activities and Prospects ,  Who ... companies? And what are their sales potentials? Discover, ... you see results, trends, opportunities and revenue forecasting. ...
(Date:5/3/2016)... , ... May 03, 2016 , ... According to world ... for definitive prostate cancer treatment, patients traditionally had two main treatment options: surgery or ... would be made. , New technology has enabled doctors to administer higher doses ...
(Date:5/2/2016)... , May 2, 2016 Q ... its technology partner Mannin Research Inc. will be attending ... which takes place from May 1-5, 2016 in ... be meeting with its vendors and research partners. The ... development goals and other collaborative opportunities for the MAN-01 ...
(Date:5/2/2016)... ... May 02, 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) ... of three Secure Remote Desktop modules to its flagship X-Win32 PC X server. ... Unix servers to the user’s PC over encrypted SSH. , Traditionally, users of PC ...
Breaking Biology Technology:
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
(Date:3/3/2016)... and DE SOTO, Kansas , March ... Detection Plus® to offer Oncimmune,s Early CDT®-Lung, a ... early detection of lung cancer Early CDT®-Lung ... and individuals. --> Early CDT®-Lung test to ... --> Oncimmune, a leader in early cancer ...
Breaking Biology News(10 mins):